导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 19.08% | 303/4773 |
| 近一周 | -2.44% | 3011/5458 |
| 近一月 | -8.12% | 4249/5421 |
| 近一季 | -13.77% | 4561/5205 |
| 近半年 | 18.49% | 178/4920 |
| 近一年 | 26.93% | 243/4361 |
| 近两年 | 107.16% | 550/2954 |
| 近三年 | 69.86% | 304/2253 |
| 成立以来 | 115.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.76% 2468/4961 |
66.28% 322/5312 |
- - |
- - |
| 2025 | 39.11% 843/4813 |
-2.33% 2874/3635 |
2.73% 1398/4076 |
32.25% 1088/4524 |
4.84% 477/4813 |
| 2024 | 7.66% 1638/3463 |
-0.89% 1150/2808 |
-2.68% 1226/3014 |
16.06% 1552/3129 |
-3.83% 2391/3463 |
| 2023 | -24.38% 1969/2656 |
-0.53% 1803/2280 |
-4.25% 1103/2385 |
-16.36% 2250/2515 |
-5.06% 1243/2655 |
| 2022 | -27.49% 1482/2207 |
-18.28% 1316/1919 |
7.53% 456/2016 |
-15.91% 1368/2113 |
-1.87% 1751/2208 |
| 2021 | 19.41% 194/1822 |
-6.15% 980/1255 |
34.14% 30/1330 |
-6.96% 1010/1466 |
1.94% 744/1822 |
| 2020 | 90.72% 22/1250 |
6.74% 39/1028 |
34.79% 22/1067 |
6.40% 843/1164 |
24.60% 34/1184 |
| 2019 | - - |
- - |
- - |
6.52% 124/850 |
7.74% 402/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华夏创业板成长ETF联接A VS. 长安沪深300非周期A(740101) |